N-((1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-3-(((4'S)-6'-(2,2-dimethylpropyl)-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-yl)amino)-2-hydroxypropyl)acetamide | 939456-76-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 英文名称: N-((1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-3-(((4'S)-6'-(2,2-dimethylpropyl)-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-yl)amino)-2-hydroxypropyl)acetamide
• 英文别名: N-[(2S,3R)-1-(1,3-benzodioxol-5-yl)-4-[[(4S)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxybutan-2-yl]acetamide
• CAS: 939456-76-5
• 化学式: C₂₉H₃₉N₃O₅
• 分子量: 509.646
• InChiKey: KHOYMTLYNVQONU-KMDXXIMOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-乙酰基咪唑 、 (2R,3S)-3-amino-4-(benzo[d][1,3]dioxol-5-yl)-1-((S)-6′-neopentyl-3′,4′-dihydrospiro[cyclobutane-1,2′-pyrano[2,3-b]pyridine]-4′-ylamino)butan-2-ol trichloride 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 以72%的产率得到N-((1S,2R)-1-(1,3-benzodioxol-5-ylmethyl)-3-(((4'S)-6'-(2,2-dimethylpropyl)-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-yl)amino)-2-hydroxypropyl)acetamide
  参考文献：
  名称：

  Design and Preparation of a Potent Series of Hydroxyethylamine Containing β-Secretase Inhibitors That Demonstrate Robust Reduction of Central β-Amyloid

  摘要：

  A series of potent hydroxyethyl amine (HEA) derived inhibitors of beta-site APP cleaving enzyme (BACE1) was optimized to address suboptimal pharmacokinetics and poor CNS partitioning. This work identified a series of benzodioxolane analogues that possessed improved metabolic stability and increased oral bioavailability. Subsequent efforts focused on improving CNS exposure by limiting susceptibility to Pgp-mediated efflux and identified an inhibitor which demonstrated robust and sustained reduction of CNS beta-amyloid (A beta) in Sprague-Dawley rats following oral administration.

  DOI：

  10.1021/jm300119p

文献信息

• Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
  申请人：Zhong Wenge

  公开号：US20090275602A1

  公开（公告）日：2009-11-05

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I or Formula II wherein R 1a , R 1b , R 1c , B, R 3 , R 4 , R 5 and W of Formula I, and R 1a , R 1b , R 1c , R 2 , R 2a , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , W, X, Z, m and n of Formula II are defined herein. The invention also provides compounds of Formula III, sub-Formulas II-A-II-D, sub-Formulas III-A-III-D and Formula IV. The invention further includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, AD, cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formulas I, II, III, IV and sub-formulas thereof, intermediates and processes useful for the preparation of compounds of Formulas I, II, III, IV and sub-formulas thereof.

  本发明涉及一类新的化合物，可用于调节β-分泌酶酶活性以及治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施方式中，该化合物具有一般的I式或II式，其中I式中的R1a、R1b、R1c、B、R3、R4、R5和W，以及II式中的R1a、R1b、R1c、R2、R2a、R3、R4、R5、A1、A2、A3、A4、W、X、Z、m和n在此定义。本发明还提供了III式、子式II-A-II-D、子式III-A-III-D和IV式的化合物。本发明还包括将这些化合物用于制备药物组合物，用于治疗、预防或治疗与β-分泌酶蛋白活性相关的疾病和病况，例如AD、认知缺陷和障碍、精神分裂症和其他类似的中枢神经系统疾病。本发明还涉及I、II、III、IV式及其子式的进一步实施方式，以及制备I、II、III、IV式及其子式的化合物的中间体和过程。
• Beta-secretase modulators and methods of use
  申请人：Zhong Wenge

  公开号：US20070185144A1

  公开（公告）日：2007-08-09

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, W, R 3 , R 4 , R 5 , i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新型化合物，可用于调节β-分泌酶酶活性和治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施方式中，化合物具有通式I，其中A、B、W、R3、R4、R5、i和j在此定义。本发明还包括包含一个或多个通式I化合物的药物组合物，以及使用这些化合物的方法，包括通过将通式I化合物或包含它们的组合物给予受试者治疗AD和相关疾病。本发明还包括通式II和III的进一步实施方式，以及用于制备本发明化合物的中间体和过程。
• BETA-SECRETASE MODULATORS AND METHODS OF USE
  申请人：Zhong Wenge

  公开号：US20100222338A1

  公开（公告）日：2010-09-02

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, W, R 3 , R 4 , R 5 , i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新型化合物，可用于调节β-分泌酶酶活性和治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施例中，该化合物具有一般式I，其中A、B、W、R3、R4、R5、i和j在此被定义。本发明还包括包含一种或多种I式化合物的制药组合物，以及使用这些化合物的方法，包括通过将I式化合物或包含它们的组合物用于治疗AD和相关疾病来给受试者施用。本发明还包括进一步的II式和III式的实施例，以及用于制备本发明化合物的中间体和方法。
• SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
  申请人：ZHONG Wenge

  公开号：US20120220583A1

  公开（公告）日：2012-08-30

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase activity and for the treatment of diseases, including Alzheimer's disease (AD) and related CNS conditions, mediated thereby. In one embodiment, the compounds have a general Formula I or Formula II wherein R 1a-1c , B, R 3-5 and W of Formula I, and R 1a-1c , R 2-5 , A 1-4 , W, X, Z, m and n of Formula II are defined herein. The invention further provides compounds of Formula III and IV and sub-Formulas II-A-II-D and III-A-III-D. The compounds may be used in pharmaceutical compositions for treating, prophylactically or therapeutically, disorders related to the activity of beta-secretase protein, including without limitation, AD, cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions.

  本发明涉及一种新的化合物类别，用于调节Beta-分泌酶活性和治疗由此介导的疾病，包括阿尔茨海默病（AD）和相关的中枢神经系统疾病。在一种实施方案中，所述化合物具有通式I或通式II，其中式I中的R1a-1c、B、R3-5和W，式II中的R1a-1c、R2-5、A1-4、W、X、Z、m和n在此定义。本发明还提供了通式III和IV以及亚式II-A-II-D和III-A-III-D的化合物。所述化合物可用于制备药物组合物，用于预防或治疗与Beta-分泌酶蛋白活性相关的疾病，包括但不限于AD、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。
• US8163909B2
  申请人：——

  公开号：US8163909B2

  公开（公告）日：2012-04-24